ASCENTAGE-B (06855.HK)  +0.050 (+0.100%)    Short selling $18.57M; Ratio 10.130%   opened up 14.97% (17th) today, peaking at $29.8. It last printed at $26.8, up 16.27%, on volume of 4.52 million shares and turnover of $123 million.

ASCENTAGE-B announced that it issued 24.3073 million new shares to Takeda International, a wholly-owned subsidiary of Takeda Pharmaceuticals, Japan, representing 7.73% of its enlarged share capital. The total consideration was US$75 million (approximately HK$586 million), equivalent to a price of HK$24.0985 per share, representing a premium of 4.55% over the closing price on the last trading day (14th). The net proceeds will be utilized for the development of core products and key product candidates.

In addition, ASCENTAGE-B granted an exclusive option to Takeda International to enter into an Exclusive Option Agreement for olverembatinib (HQP1351), a core drug candidate for the treatment of drug-resistant chronic myelogenous leukemia (CML), which is the Company's first approved product. If Takeda International exercises the option, the Option would allow Takeda International to license global rights to develop and commercialize olverembatinib in all territories outside of, among others, mainland China, Hong Kong, Macau and Taiwan, China.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-30 16:25.)